Autopsy report · NCT01045928

Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma

“Extreme toxicity in Phase I, study did not proceed to Phase II”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 2 months before it stopped.
• 5 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Case Comprehensive Cancer Center

Sponsor type

University, hospital or other

Conditions

Adult Non-Hodgkin Lymphoma; Adult Grade III Lymphomatoid Granulomatosis; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma

Interventions

lenalidomide; rituximab; polymerase chain reaction; nucleic acid sequencing; polymorphism analysis; flow cytometry

Participants

5

Sites

3

Countries

United States

Trials that died the same way

• Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-small Cell Cell Lung Cancer
  “Study terminated due to toxicity” (69% match in meaning)
• A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer
  “Extreme toxicity” (68% match in meaning)
• Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer
  “The study used a two-stage design. After stage one, the study was terminated due to excess toxicity.” (68% match in meaning)
• Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer
  “Study did not meet Phase Ib primary objective to establish the maximum tolerated dose/recommended dose for Phase II” (67% match in meaning)
• Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients
  “The study has been prematurely terminated due to the onset of 2 dose limiting toxicities in 2 patients.” (65% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.